Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study

L. M. Cupini, E. Troisi, F. Placidi, M. Diomedi, M. Silvestrini, G. Argiro, G. Bernardi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We have investigated the prolactin response to bromocriptine (BRC), a D2 dopamine receptor agonist in migrainous women before and after treatment with flunarizine. We evaluated whether this test was predictive of therapeutic efficacy of flunarizine treatment and whether the therapeutic response to flunarizine treatment was related to its effect on dopaminergic system at tuberoinfundibular level. Ten migrainous women underwent a BRC test in the late follicular phase before and after 1 and 3 months of treatment with flunarizine 10 mg at bedtime. Blood samples of prolactin (PRL), growth hormone, follicle-stimulating hormone, luteinizing hormone, estradiol and progesterone were taken at basal condition. PRL was also evaluated 1 and 2 h after BRC (2.5 mg) administration. Each patient kept a daily headache diary for 1 month prior to the test and throughout the study. The level of PRL inhibition after BRC administration, observed before flunarizine treatment, was not predictive of the therapeutic response observed after 1 and 3 months of treatment. The effect of flunarizine on PRL level was not related to the therapeutic efficacy of the drug. These data suggest that flunarizine does not attenuate the activity of dopaminergic neurons in migrainous patients, and that the antimigraine effect of flunarizine does not seem related to its action on dopaminergic system at least at tuberoinfundibular level.

Original languageEnglish
Pages (from-to)27-31
Number of pages5
JournalCephalalgia
Volume19
Issue number1
DOIs
Publication statusPublished - 1999

Fingerprint

Flunarizine
Prolactin
Bromocriptine
Therapeutics
Clinical Studies
Follicular Phase
Dopaminergic Neurons
Dopamine Agonists
Follicle Stimulating Hormone
Luteinizing Hormone
Growth Hormone
Progesterone
Headache
Estradiol

Keywords

  • Bromocriptine
  • Flunarizine
  • Migrainous

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Cupini, L. M., Troisi, E., Placidi, F., Diomedi, M., Silvestrini, M., Argiro, G., & Bernardi, G. (1999). Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study. Cephalalgia, 19(1), 27-31. https://doi.org/10.1046/j.1468-2982.1999.1901027.x

Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study. / Cupini, L. M.; Troisi, E.; Placidi, F.; Diomedi, M.; Silvestrini, M.; Argiro, G.; Bernardi, G.

In: Cephalalgia, Vol. 19, No. 1, 1999, p. 27-31.

Research output: Contribution to journalArticle

Cupini, LM, Troisi, E, Placidi, F, Diomedi, M, Silvestrini, M, Argiro, G & Bernardi, G 1999, 'Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study', Cephalalgia, vol. 19, no. 1, pp. 27-31. https://doi.org/10.1046/j.1468-2982.1999.1901027.x
Cupini, L. M. ; Troisi, E. ; Placidi, F. ; Diomedi, M. ; Silvestrini, M. ; Argiro, G. ; Bernardi, G. / Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study. In: Cephalalgia. 1999 ; Vol. 19, No. 1. pp. 27-31.
@article{f6878328ca044facab9480c4755ec832,
title = "Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study",
abstract = "We have investigated the prolactin response to bromocriptine (BRC), a D2 dopamine receptor agonist in migrainous women before and after treatment with flunarizine. We evaluated whether this test was predictive of therapeutic efficacy of flunarizine treatment and whether the therapeutic response to flunarizine treatment was related to its effect on dopaminergic system at tuberoinfundibular level. Ten migrainous women underwent a BRC test in the late follicular phase before and after 1 and 3 months of treatment with flunarizine 10 mg at bedtime. Blood samples of prolactin (PRL), growth hormone, follicle-stimulating hormone, luteinizing hormone, estradiol and progesterone were taken at basal condition. PRL was also evaluated 1 and 2 h after BRC (2.5 mg) administration. Each patient kept a daily headache diary for 1 month prior to the test and throughout the study. The level of PRL inhibition after BRC administration, observed before flunarizine treatment, was not predictive of the therapeutic response observed after 1 and 3 months of treatment. The effect of flunarizine on PRL level was not related to the therapeutic efficacy of the drug. These data suggest that flunarizine does not attenuate the activity of dopaminergic neurons in migrainous patients, and that the antimigraine effect of flunarizine does not seem related to its action on dopaminergic system at least at tuberoinfundibular level.",
keywords = "Bromocriptine, Flunarizine, Migrainous",
author = "Cupini, {L. M.} and E. Troisi and F. Placidi and M. Diomedi and M. Silvestrini and G. Argiro and G. Bernardi",
year = "1999",
doi = "10.1046/j.1468-2982.1999.1901027.x",
language = "English",
volume = "19",
pages = "27--31",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study

AU - Cupini, L. M.

AU - Troisi, E.

AU - Placidi, F.

AU - Diomedi, M.

AU - Silvestrini, M.

AU - Argiro, G.

AU - Bernardi, G.

PY - 1999

Y1 - 1999

N2 - We have investigated the prolactin response to bromocriptine (BRC), a D2 dopamine receptor agonist in migrainous women before and after treatment with flunarizine. We evaluated whether this test was predictive of therapeutic efficacy of flunarizine treatment and whether the therapeutic response to flunarizine treatment was related to its effect on dopaminergic system at tuberoinfundibular level. Ten migrainous women underwent a BRC test in the late follicular phase before and after 1 and 3 months of treatment with flunarizine 10 mg at bedtime. Blood samples of prolactin (PRL), growth hormone, follicle-stimulating hormone, luteinizing hormone, estradiol and progesterone were taken at basal condition. PRL was also evaluated 1 and 2 h after BRC (2.5 mg) administration. Each patient kept a daily headache diary for 1 month prior to the test and throughout the study. The level of PRL inhibition after BRC administration, observed before flunarizine treatment, was not predictive of the therapeutic response observed after 1 and 3 months of treatment. The effect of flunarizine on PRL level was not related to the therapeutic efficacy of the drug. These data suggest that flunarizine does not attenuate the activity of dopaminergic neurons in migrainous patients, and that the antimigraine effect of flunarizine does not seem related to its action on dopaminergic system at least at tuberoinfundibular level.

AB - We have investigated the prolactin response to bromocriptine (BRC), a D2 dopamine receptor agonist in migrainous women before and after treatment with flunarizine. We evaluated whether this test was predictive of therapeutic efficacy of flunarizine treatment and whether the therapeutic response to flunarizine treatment was related to its effect on dopaminergic system at tuberoinfundibular level. Ten migrainous women underwent a BRC test in the late follicular phase before and after 1 and 3 months of treatment with flunarizine 10 mg at bedtime. Blood samples of prolactin (PRL), growth hormone, follicle-stimulating hormone, luteinizing hormone, estradiol and progesterone were taken at basal condition. PRL was also evaluated 1 and 2 h after BRC (2.5 mg) administration. Each patient kept a daily headache diary for 1 month prior to the test and throughout the study. The level of PRL inhibition after BRC administration, observed before flunarizine treatment, was not predictive of the therapeutic response observed after 1 and 3 months of treatment. The effect of flunarizine on PRL level was not related to the therapeutic efficacy of the drug. These data suggest that flunarizine does not attenuate the activity of dopaminergic neurons in migrainous patients, and that the antimigraine effect of flunarizine does not seem related to its action on dopaminergic system at least at tuberoinfundibular level.

KW - Bromocriptine

KW - Flunarizine

KW - Migrainous

UR - http://www.scopus.com/inward/record.url?scp=0033017912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033017912&partnerID=8YFLogxK

U2 - 10.1046/j.1468-2982.1999.1901027.x

DO - 10.1046/j.1468-2982.1999.1901027.x

M3 - Article

VL - 19

SP - 27

EP - 31

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 1

ER -